arrow_back Back Filing freshness 10-Q FY 2022 SEC EDGAR

download Export Data

Bioquest Corp

BQST

— Price unavailable

5 Visible periods

16 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

Bioquest Corp shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 149.2% ↗

FCF / Share —

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-821.02K

↑ +64.7% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

100

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 1 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
Net Income Growth YoY (%)	64.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-376.2% Weak Weak Year-over-year change in net income	-5795.8% Weak Weak Year-over-year change in net income	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
FCF / Net Income (x)	0.14x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.08x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
Return on Invested Capital (%)	149.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	98.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-11.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-72.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-2438.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12871.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-90.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	189.6% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1164%)	131.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+776%)	-55.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-472%)	-91.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-712%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
Interest Coverage (x)	-27.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	-58.47x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-33.54K	$-260.00	$-543.85K	$-7.98K	$-946.00

📊 What does each share earn? 3 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
Basic EPS, GAAP (USD)	$-0.08	—	—	—	—
Book Value per Share (USD)	$-0.04	$-0.20	$0.02	$0.00	—
Tangible Book Value per Share (USD)	$-0.04	$-0.20	$0.02	$0.00	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
Working Capital (USD)	$-432.99K	$-1.77M	$875.20K	$7.88K	—
Total Equity (USD)	$-432.99K	$-1.77M	$875.20K	$9.02K	$2.74K

📋 What is driving earnings? 4 metrics

Metric	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2014 10-K ↗	FY 2019 Apr 30, 2013 10-K ↗	FY 2018 Apr 30, 2012 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$0.00	$0.00	—
Depreciation Expense (USD)	—	—	$648.00	$648.00	—
Net Income, GAAP (USD)	$-821.02K	$-2.32M	$-487.99K	$-8.28K	—
Operating Cash Flow (USD)	$-116.72K	$-193.21K	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 22 quarters

Bioquest Corp

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BQST with peers